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Summary
Primary intestinal lymphangiectasia (PIL) is rare disorder characterized by congenital mal-
formation or obstruction of intestinal lymphatic drainage; it is responsible for protein losing 
enteropathy leading to lymphopenia, hypoalbuminemia and hypogammaglobulinemia. A 
low-fat diet associated with medium-chain triglyceride supplementation is the cornerstone of 
PIL management. The administration of intravenous immunoglobulins does not always lead 
to satisfactory plasma levels and therefore the replacement therapy with immunoglobulins is 
controversial. We describe here the case of a patient with PIL and severe hypogammaglobulin-
emia treated with immunoglobulins. The striking aspect of this case is the clinical and sero-
logical benefit obtained with the subcutaneous compared to the intravenous immunoglobulins 
administration.
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Introduction
Primary intestinal lymphangectasia (PIL), also known as Wald-
mann’s disease, is a rare disorder characterized by dilated intes-
tinal lymph vessels resulting in lymph leakage into small bowel 
lumen that leads to protein-losing enteropathy and ultimately 
to lymphopenia, hypoalbuminemia and hypogammaglobu-
linemia (1). The last one is not only due to protein loss, but 
also to B cells defect characterised by a decreased number of B 
lymphocytes, a defective production of immunoglobulins and a 
poor antibody response (2,3). Therefore, in patients with PIL, 
the risk of pyogenic bacterial infections and the occurrence of 
malignancy, especially lymphomas, is increased. Even if low fat 
diet associated with supplementary medium chain tryglicerides 
(MCT) remains the cornerstone of PIL medical management 
(4), other medications have recently been taken into consider-
ation (i.e. antiplasmin and octreotide) whose efficacy is variable 
and insufficiently evaluated (1). Among the therapeutic options, 
the replacement therapy with immunoglobulins is controversial 
but needs to be considered in patients with severe hypogamma-
globulinemia and recurrent infections. Indeed, in these patients 
the administration of Intravenous Immunoglobulins (IVIg) 
does not always guarantee the achievement of satisfactory plas-
ma levels because of both pharmacodynamics of IVIg and loss 
of the immunoglobulins from the gastrointestinal tract.
We describe here the case of a young man with PIL, who de-
veloped secondary immunological abnormalities, treated with 
the specific diet and Subcutaneous Immunoglobulins (SCIg) 
obtaining clinical and immunological improvement. According 
to our knowledge this is the first report of a case of PIL treated 
with SCIg.
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The patient experienced good health till the age of 23 years, 
when suddenly he started to complain of recurrent upper and 
lower airways infections. The patient was treated with several 
antibiotics without clinical benefit. He performed a chest and 
paranasal sinuses CT scan that showed several bronchiectasis 
and nasal turbinates’ mucosal hyperplasia. A new evaluation of 
the immunological defects confirmed severe hypogammaglob-
ulinemia (IgG 2.28 g/L, IgG1 1.82 g/L, IgG2 0.70 g/L, IgG3 
0.17 g/L, IgG4 0.11 g/L, IgA < 0.06 g/L, IgM < 0.05 g/L) and 
a lymphocytopenia with B and T cell depletion (WBC 4160/
mmc, lymphocytes 420/mmc). Therefore, we decided to start 
the administration of IVIg as replacement therapy (0,4 g/kg per 
month). Even if this treatment obtained a slight improvement 
in the recurrence of infections, the serum IgG levels remained 
unsatisfactory (figure 1). In order to gain higher titres of IgG 
and a better quality of life we switched to SCIg (10 g every 10 
days) with very good results on the persistence of acceptable 
levels of IgG (figure 1).
The striking aspect of this case is the clinical and serological 
benefit on immunodeficiency obtained with the SCIg compared 
to the IVIg administration (figure 1).
Case report
MA, a 26 years old Caucasian man, was diagnosed to have PIL 
with secondary immunological defect and congenital peripheral 
oedema at the age of 3. At birth he presented with right arm and 
leg pitting oedema and, at 7 months of age, he underwent a de-
rivative lymphatic microsurgery in the upper arm. The second 
surgery was not performed because of immunological defects: 
decreased number of T and B cells and severe hypogammaglob-
ulinemia. At the age of 3 years, the patient presented clinical 
signs of malabsorption such as abdominal pain, nausea, vom-
iting, loss and inability to gain weight, growth retardation and 
fatigue. Therefore, the patient underwent gastroduodenoscopy 
and duodenum biopsies which revealed diffuse dilated muco-
sal and submucosal lymph vessels, confirming the diagnosis 
of PIL. The patient started a specific diet with medium chain 
tryglicerides obtaining clinical improvement. A new laboratory 
evaluation was also performed and confirmed the previous find-
ings of immunological abnormalities such as hypogammaglob-
ulinemia, with an increase number of NK cells and decreased 
number of B and T cells. Moreover, a nearly absent response to 
“in vitro” stimulation and to vaccines was observed.
Figure 1 - Plasma levels of Immunoglobulins before and after the administration of SCIg. The beginning of SCIg administration 
is indicated as T0. Before T0 the plasma levels of Ig was evaluated monthly. From T0 the dosage of plasma Immunoglobulins was performed 
every 5 days (T5; T10; T15…)
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month (the same monthly dosage previously used by the patient 
via IV route). As shown in figure 1, using the new therapeutic 
regimen we have observed a progressive increase in plasma lev-
els of IgG, which slowly edged up and stabilized around 6 g/L 
(IgG1 3.67 g/L, IgG2 1.51 g/L, IgG3 0.19 g/L, IgG4 0.11 g/L), 
result never observed before using the IVIg route.
We now want to evaluate whether SCIg administration leads 
not only to a more stable levels of circulating Ig, but also to 
modulation of immune response as shown for IVIg (7-9).
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Discussion
Intravenous Immunoglobulins are a therapeutic compound ob-
tained from the serum IgG fraction pooled by several thousands 
of healthy donors. It has been used for years as a replacement 
therapy in a wide range of primary and secondary immunodefi-
ciencies, and represents the first therapeutic option for antibody 
deficiencies (5). Immunoglobulins can be administered via SC 
or IV route; SCIg preparations were introduced in the 1980s 
in US and Europe. However, slow infusion technique and low 
concentration of available preparations at that time, made SCIg 
less attractive than IVIg to patients and healthcare profession-
als. Therefore, IVIg, which allowed infusions of higher monthly 
doses, became the best route of administration. Pure and high-
ly concentrated SCIg preparations with relatively low viscosity 
that allow a relatively rapid administration have recently been 
developed. Whereas IVIg is infused every 3-4 weeks, SCIg is ad-
ministered once a week or biweekly, with the total IVIg monthly 
dose divided in smaller doses. The SC administration is charac-
terised by a progressive release of IgG into the circulation ob-
taining a more stable serum IgG levels. Moreover, a multicentre 
European study showed that SCIg increases serum IgG levels 
of 17.7% compared to IVIg using equivalent doses of Ig, in 
patients who switched from the IV to the SC route (6). Subcu-
taneous Immunoglobulins are easy to use and to self-administer, 
providing patients with flexibility and improved quality of life. 
Furthermore, patients require less assistance from healthcare 
professionals, reducing the cost associated with Ig replacement 
therapy, and take a greater control over their treatment.
For all these reasons and since the patient had not lymphangec-
tasia on the abdominal wall, we chose to shift form IVIg to SCIg 
replacement therapy.
Among all the SCIg preparations available, we used Hizentra®, 
a 20% (200 g/L) ready-to-use liquid preparation of polyvalent 
human IgG for subcutaneous administration. Currently, it is 
the only 20% SCIg therapy approved by the US Food and Drug 
Administration and European Medicines Agency for treatment 
of primary and secondary immunodeficiencies. 
The choice of Hizentra® lead us to perform the administration 
of SCIg once every 10 days, for a total amount of 30 g of Ig per 
